FDA approves Novavax COVID-19 vaccine
Digest more
JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
It's not clear if recommendation will be removed entirely or people will be told to consult their doctors. Read more at straitstimes.com. Read more at straitstimes.com.
Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is soaring after the company's COVID-19 vaccine was approved by the US Food and Drug Administration (FDA).
FDA Commissioner Marty Makary said his agency plans to release a new framework for vaccine approvals in “coming days.”
Explore more
The authorities are recommending vulnerable individuals get the latest vaccinations. Read more at straitstimes.com. Read more at straitstimes.com.